News and events

June 17, 2020

InSysBio announces the appointment of Dr. Neil Benson as Principal Consultant in area of business development

(Edinburgh-Moscow-16.06.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, is proud to announce its new team member Dr. Neil Benson! Dr. Benson has joined InSysBio as Principal Consultant in area of business development of both INSYSBIO LLC and INSYSBIO UK LIMITED. In his capacity as Principal Consultant to InSysBio, he will support further development of the outstanding IO and AD QSP offering of the company.

InSysBio to release the new version of Cytocon DB 1.1.6.4

June 12, 2020

We are glad to announce the release of the new version of Cytocon DB 1.1.6.4. The DB was significantly extended with new data due to well-coordinated workflow of Cytocon DB team and its new members. Namely, 54 diseases, 24 tissues, 42 molecules, 24 cells and 3701 concentrations were introduced.

InSysBio to perform the first step in development of COVID-19 QSP model

June 8, 2020

InSysBio has performed the first step in the direction of development of QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.

InSysBio to present IRT Navigator 3

June 5, 2020

InSysBio presents IRT Navigator 3 which is an application software providing intuitive interface to work with the Immune Response Template Database in accordance with the user’s needs. It supplies the navigation within the schemes and components and efficient development of QSP models based on IRT Database.

InSysBio to announce the launch of QSP model of COVID-19

June 2, 2020

The new open source project to be developed and updated Online

InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces the launch of its fundamentally new project in response to the ongoing global threat, the open source QSP model of COVID-19. In accordance with its mission, which is to assist pharmaceutical industry to speed up the delivery of the cure to patients, InSysBio team could not stay aside. Thus, the aim of the new project is to develop QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.

InSysBio to take part in AACR Virtual Annual Meeting II

CONFERENCE

UPCOMING EVENT

May 15, 2020

InSysBio announces its participation in AACR Virtual Annual Meeting II June 22-24, American Association for Cancer Research Annual Meeting which is held virtually this year due to COVID-19 spread. Today InSysBio team's abstracts were published on AACR website

InSysBio innovates its Immune Response Template Database

April 15, 2020

IRT version 3.1.0 acquires some principal upgrades

(Moscow – 15.04.2020) InSysBio is one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling has published the new version of IRT database, one of its core products.

InSysBio to announce the release of its new database Cytocon DB 1.1

March 31, 2020

Cytocon DB 1.1 facilitates access of QSP modelers to baseline in vivo data in public domain

(Moscow - 31.03.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) platform development and provision, has released its new Cytocon DB 1.1. The name of the database derives from Cell and cYTOkine CONcentrations.

InSysBio to share the news from QSPC2020 management

CONFERENCE

UPCOMING EVENT

March 10, 2020

Today we have received the concerning news from QSPC2020 organizers about the cancellation of the conference in response to COVID-19 outbreak continuation. Quantitative Systems Pharmacology Conference 2020 was planned to be held in April 22-24, 2020 Leiden, The Netherlands. InSysBio team was prepared to present 10 posters

13th InSysBio Annual Internal Scientific Meeting

CONFERENCE

March 3, 2020

26-28 February 2020 InSysBio QSP-company held its 13th Annual Internal Scientific Meeting. InSysBio team presented the results of 2019 year professional progress. Every member demonstrated their personal achievements and shared the plans for the future development. Oleg Demin, InSysBio CEO and founder, summarized all the company’s advancement of the year 2019.